15.04

6.29% 0.89

Aurinia Pharmaceuticals Inc (AUPH)

Overview News Price History Option Chain Financials Why AUPH Down? Discussions Forecast Stock Split

Aurinia Pharmaceuticals Inc stock is traded at $15.04, with a volume of 1.74M. It is up +6.29% in the last 24 hours and up +3.16% over the past month. Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Previous Close:

$14.15

Open:

$14.57

24h Volume:

1.74M

Relative Volume:

1.68

Market Cap:

$1.98B

Revenue:

$265.81M

Net Income/Loss:

$77.84M

P/E Ratio:

26.80

EPS:

0.5611

Net Cash Flow:

$120.40M

1W Performance:

+4.23%

1M Performance:

+3.16%

6M Performance:

+20.03%

1Y Performance:

+86.14%

1-Day Range:

$14.42

$15.14

1-Week Range:

$13.52

$15.14

52-Week Range:

$6.825

$16.54

Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile

Name

Aurinia Pharmaceuticals Inc

Sector

Healthcare (1106)

Industry

Biotechnology (621)

Phone

250-744-2487

Address

#140, 14315 - 118 AVENUE, EDMONTON, BC

Employee

300

Twitter

@AuriniaPharma

Next Earnings Date

2024-11-07

Latest SEC Filings

AUPH's Discussions on Twitter

Compare AUPH vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AUPH Aurinia Pharmaceuticals Inc	15.04	1.87B	265.81M	77.84M	120.40M	0.5611
VRTX Vertex Pharmaceuticals Inc	477.89	120.48B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	787.50	81.05B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	749.56	46.33B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	327.30	42.26B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	299.02	32.87B	5.36B	287.73M	924.18M	2.5229

Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-03-25	Downgrade	Leerink Partners	Outperform → Market Perform
Nov-07-25	Upgrade	Jefferies	Hold → Buy
Nov-05-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jul-30-25	Resumed	H.C. Wainwright	Buy
Nov-04-22	Downgrade	Oppenheimer	Outperform → Perform
May-05-22	Resumed	Cantor Fitzgerald	Overweight
Dec-10-21	Upgrade	Oppenheimer	Perform → Outperform
Oct-28-21	Downgrade	Oppenheimer	Outperform → Perform
Jan-25-21	Reiterated	H.C. Wainwright	Buy
Nov-03-20	Reiterated	H.C. Wainwright	Buy
Jun-17-20	Initiated	BTIG Research	Buy
May-05-20	Initiated	Cowen	Outperform
Jan-10-20	Initiated	Jefferies	Buy
Dec-16-19	Reiterated	H.C. Wainwright	Buy
Mar-16-18	Reiterated	Cantor Fitzgerald	Overweight
Feb-08-18	Initiated	RBC Capital Mkts	Outperform
Oct-30-17	Reiterated	H.C. Wainwright	Buy
May-18-17	Reiterated	H.C. Wainwright	Buy
Apr-11-17	Initiated	Cantor Fitzgerald	Overweight
Mar-22-17	Reiterated	FBR & Co.	Outperform
Dec-30-16	Reiterated	H.C. Wainwright	Buy
Aug-17-16	Reiterated	H.C. Wainwright	Buy
Jun-30-16	Initiated	H.C. Wainwright	Buy
May-08-15	Initiated	MLV & Co	Buy

View All

Aurinia Pharmaceuticals Inc Stock (AUPH) Latest News

Mar 03, 2026

Aurinia Pharmaceuticals (NASDAQ:AUPH) Director Buys $7,224,981.61 in Stock - MarketBeat

Mar 03, 2026